EGFR mutations are associated with higher incidence of distant metastases and smaller tumor size in patients with non-small-cell lung cancer based on PET/CT scan

2015 ◽  
Vol 33 (1) ◽  
Author(s):  
Jian Guan ◽  
Min Chen ◽  
Nanjie Xiao ◽  
Lu Li ◽  
Yue Zhang ◽  
...  
2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 19112-19112
Author(s):  
G. Franz ◽  
L. Kronish ◽  
R. U. Osarogiagbon ◽  
L. Thompson ◽  
M. Jahanzeb

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e19038-e19038
Author(s):  
S. Virani ◽  
M. Almubarak ◽  
G. Marano ◽  
J. S. Rogers

e19038 Background: Up to one-third of non-small cell lung cancer (NSCLC) patients are diagnosed with brain metastasis. Our study aims to evaluate the role of whole body and brain FDG-PET/CT in detecting asymptomatic brain metastasis in this population. Methods: We performed a retrospective chart review of 282 consecutive non-small cell lung cancer patients between February of 2005 and June of 2008. 60 patients with brain metastasis were identified. Information regarding tumor histology and presence of neurological symptoms at the time of discovery of brain metastasis was collected. In addition, data was acquired from brain MRI and PET/CT (with IV contrast) reports including: study date, findings and any change in staging secondary to the study. Results: The median age was 63 years (47 % women). 39 (65%) of the patients had neurological symptoms at the time of discovery of brain metastasis. PET/CT scan with IV contrast was performed in 53 patients with brain metastasis. For patients who had a PET/CT scan, the histological types were: adenocarcinoma (58.4%), unclassified (22.6%), squamous (13.2%), large cell (3.8%) and other (1.8%). PET/CT scan had a sensitivity of 97.8% in detecting CNS metastasis seen on brain MRI. 19/53 patients were found to have asymptomatic brain metastasis on PET/CT scan (2 stage I, 1 stage II, 2 stage III and 13 stage IV). Overall, PET/CT scan resulted in upstaging of 5 asymptomatic and 6 symptomatic patients or 11/53 (20.7%). Conclusions: PET/CT scan with IV contrast has a high sensitivity in detecting brain metastasis in patients with NSCLC when compared to brain MRI. It is effective in detecting asymptomatic brain metastasis in this population. Those patients, who initially were thought to have non-metastatic disease, are spared inappropriate aggressive surgery or radiation. No significant financial relationships to disclose.


CHEST Journal ◽  
2014 ◽  
Vol 146 (2) ◽  
pp. 406-411 ◽  
Author(s):  
Nicholas J. Pastis ◽  
Travis J. Greer ◽  
Nichole T. Tanner ◽  
Amy E. Wahlquist ◽  
Leonie L. Gordon ◽  
...  

2016 ◽  
Vol 23 (suppl 1) ◽  
pp. i52.1-i52
Author(s):  
Antonio Francisco Honguero-Martinez ◽  
M.D. Garcia-Jimenez ◽  
A. Garcia-Vicente ◽  
C. Rodriguez-Ortega ◽  
M. Genoves-Crespo ◽  
...  

2009 ◽  
Vol 23 (6) ◽  
pp. 523-531 ◽  
Author(s):  
Kazuyoshi Suga ◽  
Yasuhiko Kawakami ◽  
Atsuto Hiyama ◽  
Kazurou Sugi ◽  
Kazutomo Okabe ◽  
...  

Author(s):  
Ngo Minh Xuan ◽  
Huynh Quang Huy

Background: Small-cell lung cancer (SCLC) accounts for 15%-20% of all lung cancer cases. positron emission tomography - computed tomography (PET/CT) has become increasingly used as an initial staging tool in patients with SCLC. We aimed to explore the relationships between primary tumor 18F-FDG uptake measured as the maximum standardized uptake value (SUV max) and clinical stage at PET/CT for small cell lung cancer patients (SCLC).Methods: Patients with SCLC who underwent 18F-FDG PET/CT scans before the treatment were included in the study at Bach Mai hospital of Vietnam, from November 2014 to May 2018. The primary tumor and secondary lesion SUVmax was calculated; the tumor size was measured; the TNM status was determined mainly by FDG PET/CT imaging according to The 8th Edition of the TNM Classification for Lung Cancer were recorded. An evaluation was made of the linear relationship between tumor size, T stage, N stage, and M stages of the patients and their SUVmax using Spearman’s correlation.Results: Total 37 cases (34 men and 3 women; age range 38 - 81 years, median 64 years) were analyzed. The average of primary tumor size and SUVmax were 5.95±2.77 cm and 10.21±4.75, respectively. The SUVmax of primary tumor is significantly greater than that of nodal and distant organ metastasis (10.21±4.75 vs 8.20±4.35 and 6.44±3.17, p<0.01). There was a moderate correlation between SUVmax and tumor size (r =0.596, p<0.001), tumor stage (r = 0.502, p<0.01) but not significant with nodal stage (r =-0.218, p=0.194), metastasis stage (r = -0.055, p=0.747), and overall stage (r=-0.060, p=0.725).Conclusions: SUVmax was significantly correlated with tumor size, but not with distant metastases or lymph node involvement. Therefore, SUVmax on positron emission tomography is not predictive of the presence of metastases in patients with SCLC.


Sign in / Sign up

Export Citation Format

Share Document